Wind turbine maker to pay settlement after blade broke apart and washed up on nantucket beaches
Fiberglass fragments of the blade began washing ashore last summer during the peak of tourist season after pieces of the wind turbine at the Vineyard Wind project began falling into the Atlantic Ocean in July 2024.
GE Vernova, which agreed to the settlement, blamed a manufacturing problem at one of its factories in Canada and said there was no indication of a design flaw. It reinspected all blades made at the factory and removed other blades made there from the Vineyard Wind location. Crews in boats and on beaches, along with volunteers, collected truckloads of debris.
The company said the debris was nontoxic fiberglass fragments and that the pieces were one square foot or smaller. The settlement calls for establishing a fund, along with a process to evaluate claims from businesses and distribute payments, Nantucket officials said. The development's massive wind turbines, with blades more than 328 feet (100 meters) long, began sending electricity to the grid at the beginning of 2024.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Al Arabiya
3 days ago
- Al Arabiya
Settlement reached in investors' lawsuit against Meta CEO Mark Zuckerberg and other company leaders
WILMINGTON, Del. (AP) – A settlement was announced Thursday in court in a class action investors lawsuit against Meta CEO Mark Zuckerberg and current and former company leaders over claims stemming from the privacy scandal involving the Cambridge Analytica political consulting firm. The suit had sought billions of dollars in reimbursement for fines and legal costs. No details on the settlement were shared when it was announced in Delaware's Court of Chancery at the start of what would have been the second day of trial at which point nothing related to the settlement had been filed with the court. The attorneys involved left court without commenting. A communications representative from Meta said the company had no comment. Investors had alleged in the lawsuit that Meta did not fully disclose the risks to Facebook users that their personal information would be misused by Cambridge Analytica, a firm that supported Donald Trump's successful Republican presidential campaign in 2016. Shareholders say Facebook officials repeatedly violated a 2012 consent order with the Federal Trade Commission under which Facebook agreed to stop collecting and sharing personal data without users' consent. Facebook later sold user data to commercial partners in direct violation of the consent order and removed disclosures from privacy settings that were required under consent order, the lawsuit alleged. Facebook agreed to pay a 5.1 billion penalty to settle FTC charges in the fallout. The social media giant also faced significant fines in Europe and reached a 725 million privacy settlement with users. Shareholders wanted Zuckerberg and others to reimburse Meta an estimated 8 billion or more for the FTC fine and other legal costs. Zuckerberg and former Chief Operating Officer Sheryl Sandberg had been expected to testify. Other current and former board members including billionaires Marc Andreessen and Peter Thiel were also included as defendants. Earlier this year Sandberg was sanctioned for deleting emails from her personal account related to the Cambridge Analytica investigation. Jeffrey Zients, who served as an outside director from 2018 to 2020 avoided sanctions in the same case because his role made it less likely he had access to relevant information. Testifying on the first day of this lawsuit Zients said he had supported the FTC settlement for which shareholders were seeking reimbursement.
Al Arabiya
4 days ago
- Al Arabiya
Canada's Couche-tard drops offer to buy japanese 7-eleven convenience stores
Canadian retail chain Alimentation Couche-Tard is dropping its proposal to acquire Seven & i Holdings Co., the Japanese operator of the 7-Eleven convenience store chain, citing frustration in ongoing negotiations that showed a lack of constructive engagement. The 7-Eleven parent company rejected an offer last year, but Couche-Tard, which runs the global Circle K chain, was still interested and tried to coax a deal with the Japanese chain known here as conbini. In a letter dated July 16 and sent to the Seven & i board, Couche-Tard stressed it had made a good offer earlier this year in a proposal of 2,600 yen ($17.50) per ordinary share in cash, which it said represented a 47.6 percent premium to the stock price. The initial offer made last year was for 2,200 yen ($14.86) per share in cash. In the letter sent to media Thursday and signed by its two top executives, including founder Alain Bouchard, Couche-Tard expressed exasperation at the response it was getting from Seven & i despite repeated attempts at dialogue. 'We have been very patient and respectful throughout this process, beginning with our meeting on July 23, 2024,' the letter said. 'You have engaged in a calculated campaign of obfuscation and delay to the great detriment of 7 & i and its shareholders. We believe this approach reinforces our concerns about your approach to governance. Based on this persistent lack of good faith engagement, we are withdrawing our proposal.' Couche-Tard, which runs nearly 17,000 stores in more than 30 countries and territories, including the US, said the documents it got lacked key information, executives were no-shows at meetings, and the meetings it did have ended up being readouts of statements, not frank discussions. Seven & i acknowledged the dropped offer Thursday and said it considered talks in good faith and constructively. 'We remain fully committed to our standalone value creation plan, which we have been pursuing in parallel, and to unlocking the value of our businesses, including our North American convenience store business. Our plan is concrete and actionable,' it said in a statement. Some analysts say Seven & i's management has not fully leveraged the business's global potential or delivered enough value to shareholders and could use better marketing, although its bottom line is unlikely to be affected by US President Donald Trump's tariff policies. The 7-Eleven franchise, which spans more than 85,000 stores in Japan, the US, and Europe, has a new chief executive, Stephen Hayes Dacus, the first foreigner tapped to head 7-Eleven. Dacus, an American with a Japanese mother who has experience at Walmart and Uniqlo, has promised a leaner business by focusing on the supply chain and tailoring shop offerings to various regions. For the first quarter of this fiscal year, Seven & i reported a doubling in profits to 49 billion yen ($330 million), mainly due to previously announced sales of property and equipment at its Ito-Yokado Co. retail chain. Quarterly sales held up as a favorable exchange rate helped some overseas earnings, according to the Tokyo-based chain. The seemingly omnipresent 7-Eleven chain speckles the streets of Japan, offering everything from stationery items and rice balls to hot coffee and utility bill payments.
Al Arabiya
4 days ago
- Al Arabiya
Biocon aims to launch generic Wegovy drug for weight loss in India, Canada within two year
Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years, a top executive told Reuters, seeking to tap into a market that is estimated to grow to $150 billion globally by the early 2030s. The push comes after Danish drugmaker Novo Nordisk and US-based rival Eli Lilly saw skyrocketing demand for their obesity drugs Wegovy and Zepbound. Biopharmaceutical company Biocon plans to submit a request for approval to India's drug regulator by the end of 2026 and potentially launch in 2027 through a partner, CEO Siddharth Mittal said in an email interview on Tuesday. The company, which also makes insulin products, expects to complete late-stage trials within the next 12 to 18 months, he added. 'Biocon is actively progressing with filings for semaglutide in Canada as well as many other emerging markets,' Mittal said. Semaglutide is the active ingredient in Novo's drugs Ozempic and Wegovy, used for diabetes and weight-loss management. Indian generic drugmakers, including Dr Reddy's and Cipla, have been racing to produce cheaper versions of Wegovy when semaglutide goes off patent in 2026. Novo launched Wegovy in India for diabetes and weight-loss management in June after Lilly's Mounjaro sales doubled within a few months following its launch in the south Asian country. Biocon plans to file with Canadian regulatory authorities this quarter for generic versions of Ozempic and later this year for Wegovy versions. 'Subject to approval, we could look at a market launch in late 2026 or early 2027,' he said. Canada has not approved any such therapies yet, the company said. In addition to Canada, Biocon will focus on large emerging markets such as Brazil and Mexico in Latin America, Malaysia and Hong Kong, countries in the Middle East, as well as Australia, and New Zealand to launch obesity drugs, according to the CEO. In markets where Biocon does not have a direct presence, it is seeking local partnerships to commercialize its products, Mittal said.
